South Korea Approves Subcutaneous Keytruda for Faster Administration

South Korea's Ministry of Food and Drug Safety has granted approval for a new subcutaneous version of the immune anticancer drug Keytruda. This updated formulation significantly streamlines the administration process, reducing the required time from over 30 minutes for intravenous delivery to just 1-2 minutes. The change is expected to enhance convenience for both cancer patients and medical personnel.